BioSpace News Archive

The ongoing Covid-19 pandemic has continued to play a role in the second quarter, but we managed well.

During July, Calliditas Therapeutics AB has issued 706,676 common shares as a result of the exercise of the over-allotment option within the initial public offering on The Nasdaq Global Select Market and the concurrent private placement of common shares to certain qualified investors in Europe and certain other jurisdictions outside of the United States.

Pfizer Inc. and BioNTech SE announced an agreement with the Ministry of Health, Labour and Welfare in Japan to supply 120 million doses of their BNT162 mRNA-based vaccine candidate against SARS-CoV-2, subject to clinical success and regulatory approval, beginning in 2021.

Takeda Pharmaceutical Company Limited announced financial results for the first quarter of fiscal year 2020.

Axovant Gene Therapies Ltd, a clinical-stage company developing innovative gene therapies for neurological diseases, announced that its subsidiary has signed a three-year Clinical Supply Agreement with Oxford Biomedica plc, a leading gene and cell therapy group.

INmune Bio, Inc., a clinical-stage immunology company focused on developing treatments that harness a patient’s innate immune system to fight disease, announced that it will host a conference call on August 5, 2020 at 4:30 PM Eastern Time to discuss results for its second quarter ended June 30, 2020.

Reports revenue growth of 3% on a reported basis and 4% on an organic basis driven by Companion Animal Group Diagnostics recurring revenue growth of 7% reported and organic

Second-Quarter 2020 Worldwide Sales Were $10.9 Billion, a Decrease of 8%, Reflecting the Negative Impact of COVID-19; Excluding the Impact from Foreign Exchange, Sales Declined 5%

New Drug Application (NDA) and Marketing Authorization Application (MAA) Submissions for Pegcetacoplan in Paroxysmal Nocturnal Hemoglobinuria (PNH) Planned for the Second Half of 2020

BioLineRx Ltd., a late clinical-stage biopharmaceutical company focused on oncology, announced it will release its unaudited financial results for the quarter ended June 30, 2020 on Thursday, August 6, 2020, before the US markets open.